Incyte (NASDAQ:INCY) Reaches New 1-Year High – Here’s Why

Posted by George Bondi on Jul 10th, 2026

Incyte Corporation (NASDAQ:INCY – Get Free Report) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $118.77 and last traded at $117.0450, with a volume of 387806 shares trading hands. The stock had previously closed at $118.05.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on INCY. Citigroup reissued a “market perform” rating on shares of Incyte in a research note on Tuesday, June 2nd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Incyte in a report on Monday, June 29th. Barclays reissued an “overweight” rating on shares of Incyte in a research report on Tuesday, March 24th. Stifel Nicolaus set a $123.00 price target on shares of Incyte in a research report on Tuesday, June 9th. Finally, Jefferies Financial Group cut Incyte from a “buy” rating to a “hold” rating and lowered their price objective for the company from $120.00 to $94.00 in a research report on Monday, March 16th. Eight equities research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Incyte has a consensus rating of “Hold” and an average target price of $108.20.

Get Our Latest Research Report on INCY

Incyte Stock Performance

The company has a market capitalization of $23.35 billion, a P/E ratio of 16.49, a PEG ratio of 1.07 and a beta of 0.76. The stock has a fifty day simple moving average of $102.85 and a 200-day simple moving average of $100.39. The company has a quick ratio of 3.60, a current ratio of 3.68 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY – Get Free Report) last posted its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.38 by $0.43. Incyte had a net margin of 26.71% and a return on equity of 26.66%. The business had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the prior year, the firm earned $1.16 EPS. The firm’s quarterly revenue was up 20.9% compared to the same quarter last year. Equities analysts forecast that Incyte Corporation will post 6.61 EPS for the current year.

Insiders Place Their Bets

In other news, insider Pablo J. Cagnoni sold 18,667 shares of the firm’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $96.50, for a total transaction of $1,801,365.50. Following the completion of the sale, the insider owned 262,692 shares of the company’s stock, valued at approximately $25,349,778. This trade represents a 6.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 16.20% of the company’s stock.

Hedge Funds Weigh In On Incyte

A number of institutional investors and hedge funds have recently bought and sold shares of INCY. Jacobi Capital Management LLC raised its stake in shares of Incyte by 0.9% during the 4th quarter. Jacobi Capital Management LLC now owns 10,613 shares of the biopharmaceutical company’s stock worth $1,048,000 after purchasing an additional 99 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of Incyte by 0.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 18,870 shares of the biopharmaceutical company’s stock valued at $1,864,000 after buying an additional 100 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in Incyte by 7.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,628 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 113 shares during the last quarter. Bank of Nova Scotia increased its holdings in Incyte by 0.7% during the second quarter. Bank of Nova Scotia now owns 17,041 shares of the biopharmaceutical company’s stock worth $1,160,000 after buying an additional 124 shares during the last quarter. Finally, Perbak Capital Partners LLP raised its position in Incyte by 2.5% during the third quarter. Perbak Capital Partners LLP now owns 5,298 shares of the biopharmaceutical company’s stock worth $449,000 after acquiring an additional 129 shares in the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

About Incyte

(Get Free Report)

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.